Brief: Neurimmune Sells A Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma
22/07/2026 12:24
BRIEF-Neurimmune Sells A Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma July 22 (Reuters) - Royalty Pharma PLC RPRX.O:
NEURIMMUNE SELLS A PORTION OF ITS ROYALTY INTEREST IN CLIRAMITUG TO ROYALTY PHARMA
NEURIMMUNE: SOLD PORTION OF ITS ROYALTY INTEREST IN CLIRAMITUG TO ROYALTY PHARMA FOR UP TO $425 MILLION
NEURIMMUNE: IN Q1 OF 2027, ROYALTY PHARMA WILL PROVIDE ANOTHER $125 MILLION IN CASH TO CO
Source text: ID:nPnbxj04ba
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)